Micek Scott T, Lloyd Ann E, Ritchie David J, Reichley Richard M, Fraser Victoria J, Kollef Marin H
Department of Pharmacy, Barnes-Jewish Hospital, Washington University School of Medicine, 660 South Euclid Ave., Campus Box 8052, St. Louis, Missouri 63110, USA.
Antimicrob Agents Chemother. 2005 Apr;49(4):1306-11. doi: 10.1128/AAC.49.4.1306-1311.2005.
Pseudomonas aeruginosa bloodstream infection is a serious infection with significant patient mortality and health-care costs. Nevertheless, the relationship between initial appropriate antimicrobial treatment and clinical outcomes is not well established. This study was a retrospective cohort analysis employing automated patient medical records and the pharmacy database at Barnes-Jewish Hospital. Three hundred five patients with P. aeruginosa bloodstream infection were identified over a 6-year period (January 1997 through December 2002). Sixty-four (21.0%) patients died during hospitalization. Hospital mortality was statistically greater for patients receiving inappropriate initial antimicrobial treatment (n = 75) compared to appropriate initial treatment (n = 230) (30.7% versus 17.8%; P = 0.018). Multiple logistic regression analysis identified inappropriate initial antimicrobial treatment (adjusted odds ratio [AOR], 2.04; 95% confidence interval [CI], 1.42 to 2.92; P = 0.048), respiratory failure (AOR, 5.18; 95% CI, 3.30 to 8.13; P < 0.001), and circulatory shock (AOR, 4.00; 95% CI, 2.71 to 5.91; P < 0.001) as independent determinants of hospital mortality. Appropriate initial antimicrobial treatment was administered statistically more often among patients receiving empirical combination antimicrobial treatment for gram-negative bacteria compared to empirical monotherapy (79.4% versus 65.5%; P = 0.011). Inappropriate initial empirical antimicrobial treatment is associated with greater hospital mortality among patients with P. aeruginosa bloodstream infection. Inappropriate antimicrobial treatment of P. aeruginosa bloodstream infections may be minimized by increased use of combination antimicrobial treatment until susceptibility results become known.
铜绿假单胞菌血流感染是一种严重感染,会导致患者出现较高死亡率并产生高昂的医疗费用。然而,初始恰当的抗菌治疗与临床结局之间的关系尚未明确。本研究是一项回顾性队列分析,利用了巴恩斯犹太医院的自动患者病历和药房数据库。在6年期间(1997年1月至2002年12月)共识别出305例铜绿假单胞菌血流感染患者。64例(21.0%)患者在住院期间死亡。与接受恰当初始治疗的患者(n = 230)相比,接受不恰当初始抗菌治疗的患者(n = 75)的医院死亡率在统计学上更高(30.7%对17.8%;P = 0.018)。多因素逻辑回归分析确定不恰当的初始抗菌治疗(校正比值比[AOR],2.04;95%置信区间[CI],1.42至2.92;P = 0.048)、呼吸衰竭(AOR,5.18;95%CI,3.30至8.13;P < 0.001)和循环性休克(AOR,4.00;95%CI,2.71至5.91;P < 0.001)是医院死亡率的独立决定因素。与经验性单药治疗相比,接受经验性联合抗菌治疗革兰阴性菌的患者中,统计学上更常给予恰当的初始抗菌治疗(79.4%对65.5%;P = 0.011)。不恰当的初始经验性抗菌治疗与铜绿假单胞菌血流感染患者的更高医院死亡率相关。在药敏结果知晓之前,增加联合抗菌治疗的使用可能会尽量减少铜绿假单胞菌血流感染的不恰当抗菌治疗。